Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

Related Articles by Review for PubMed (Select 22444784)

1.

Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders.

Cheng JW, Vu H.

Clin Ther. 2012 Apr;34(4):766-87. doi: 10.1016/j.clinthera.2012.02.022. Epub 2012 Mar 22. Review.

PMID:
22444784
2.

Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.

Bovio JA, Smith SM, Gums JG.

Ann Pharmacother. 2011 May;45(5):603-14. doi: 10.1345/aph.1P644. Epub 2011 May 3. Review.

PMID:
21540406
3.

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.

Baetz BE, Spinler SA.

Pharmacotherapy. 2008 Nov;28(11):1354-73. doi: 10.1592/phco.28.11.1354. Review.

PMID:
18956996
4.

Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Burness CB, McKeage K.

Drugs. 2012 May 7;72(7):963-86. doi: 10.2165/11209080-000000000-00000. Review.

PMID:
22564134
5.

Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.

Ma TK, Yan BP, Lam YY.

Pharmacol Ther. 2011 Feb;129(2):185-94. doi: 10.1016/j.pharmthera.2010.09.005. Epub 2010 Oct 12. Review.

PMID:
20920530
6.

Dabigatran etexilate: A novel oral direct thrombin inhibitor.

Blommel ML, Blommel AL.

Am J Health Syst Pharm. 2011 Aug 15;68(16):1506-19. doi: 10.2146/ajhp100348. Review.

PMID:
21817082
7.

The pharmacology and therapeutic use of dabigatran etexilate.

Sarah S.

J Clin Pharmacol. 2013 Jan;53(1):1-13. doi: 10.1177/0091270011432169. Epub 2013 Jan 24. Review.

PMID:
23400738
8.

Dabigatran etexilate in venous thromboembolism.

Ferrer E.

Drugs Today (Barc). 2009 Oct;45(10):715-24. doi: 1396674/dot.2009.45.10.1425728. Review.

PMID:
20069135
9.
10.
11.

Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin.

Tran A, Cheng-Lai A.

Cardiol Rev. 2011 May-Jun;19(3):154-61. doi: 10.1097/CRD.0b013e3182137758. Review.

PMID:
21464643
12.

Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.

Siddiqui FM, Qureshi AI.

Expert Opin Pharmacother. 2010 Jun;11(8):1403-11. doi: 10.1517/14656566.2010.482931. Review.

PMID:
20446854
13.

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.

Holmes M, Carroll C, Papaioannou D.

Pharmacoeconomics. 2012 Feb 1;30(2):137-46. doi: 10.2165/11591590-000000000-00000. Review.

PMID:
22185183
14.

Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

McKeage K.

Pharmacoeconomics. 2012 Sep 1;30(9):841-55. doi: 10.2165/11209130-000000000-00000. Review.

PMID:
22734683
15.

Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence.

Greig SL, McKeage K.

Drugs. 2014 Oct;74(15):1785-800. doi: 10.1007/s40265-014-0304-7. Review.

PMID:
25270377
16.

Dabigatran etexilate in atrial fibrillation.

Vora A.

J Assoc Physicians India. 2013 Dec;61(12):900-2. Review.

PMID:
24968547
17.

Dabigatran: a review of clinical and pharmacoeconomic evidence.

Reddy P, Atay JK, Selbovitz LG, Connors JM, Piazza G, Block CC, Arpino PA, Berliner N, Hutter AM Jr, Fischer MA, Kuter D, Weitzman J, Sherwood GK, Almozlino A, Giugliano RP.

Crit Pathw Cardiol. 2011 Sep;10(3):117-27. doi: 10.1097/HPC.0b013e3182315c03. Review.

PMID:
21989032
18.

New options with dabigatran etexilate in anticoagulant therapy.

Maegdefessel L, Spin JM, Azuma J, Tsao PS.

Vasc Health Risk Manag. 2010 May 25;6:339-49. Review.

19.

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.

Holmes M, Carroll C, Papaioannou D.

Health Technol Assess. 2009 Sep;13 Suppl 2:55-62. doi: 10.3310/hta13suppl2/08. Review.

20.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk